Chembio Diagnostics (NASDAQ:CEMI) posted its quarterly earnings data on Thursday. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05), Fidelity Earnings reports. Chembio Diagnostics had a negative return on equity of 39.62% and a negative net margin of 32.95%. The firm had revenue of $9.72 million during the quarter.
Chembio Diagnostics stock traded down $0.47 during midday trading on Friday, reaching $4.54. The stock had a trading volume of 153,300 shares, compared to its average volume of 50,394. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.38 and a quick ratio of 1.98. The firm has a market cap of $94.85 million, a price-to-earnings ratio of -8.25 and a beta of 1.68. The firm’s fifty day simple moving average is $5.77 and its two-hundred day simple moving average is $6.15. Chembio Diagnostics has a twelve month low of $4.39 and a twelve month high of $7.90.
A number of equities analysts recently commented on the stock. Canaccord Genuity reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Chembio Diagnostics in a research note on Monday, July 22nd. ValuEngine lowered shares of Chembio Diagnostics from a “buy” rating to a “hold” rating in a research note on Monday, November 4th.
Chembio Diagnostics, Inc, together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi.
Read More: Buyback
Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.